CHE vs. LH, DGX, DVA, RCM, CRVL, AMED, AMN, MD, CCRN, and OPCH
Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Option Care Health (OPCH).
Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Laboratory Co. of America received 272 more outperform votes than Chemed when rated by MarketBeat users. Likewise, 64.18% of users gave Laboratory Co. of America an outperform vote while only 63.46% of users gave Chemed an outperform vote.
In the previous week, Laboratory Co. of America had 2 more articles in the media than Chemed. MarketBeat recorded 10 mentions for Laboratory Co. of America and 8 mentions for Chemed. Chemed's average media sentiment score of 0.76 beat Laboratory Co. of America's score of 0.63 indicating that Chemed is being referred to more favorably in the media.
Chemed pays an annual dividend of $1.60 per share and has a dividend yield of 0.3%. Laboratory Co. of America pays an annual dividend of $2.88 per share and has a dividend yield of 1.5%. Chemed pays out 8.6% of its earnings in the form of a dividend. Laboratory Co. of America pays out 57.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Laboratory Co. of America has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
Chemed has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
Chemed currently has a consensus target price of $673.50, suggesting a potential upside of 21.78%. Laboratory Co. of America has a consensus target price of $241.86, suggesting a potential upside of 25.34%. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Chemed.
Chemed has a net margin of 12.36% compared to Laboratory Co. of America's net margin of 3.52%. Chemed's return on equity of 30.52% beat Laboratory Co. of America's return on equity.
95.9% of Chemed shares are held by institutional investors. Comparatively, 95.9% of Laboratory Co. of America shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 0.9% of Laboratory Co. of America shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Laboratory Co. of America beats Chemed on 11 of the 20 factors compared between the two stocks.
Get Chemed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
